BR9907203A - "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " - Google Patents

"composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. "

Info

Publication number
BR9907203A
BR9907203A BR9907203-3A BR9907203A BR9907203A BR 9907203 A BR9907203 A BR 9907203A BR 9907203 A BR9907203 A BR 9907203A BR 9907203 A BR9907203 A BR 9907203A
Authority
BR
Brazil
Prior art keywords
disease
compound
adhd
cocaine
migraine
Prior art date
Application number
BR9907203-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9907203A publication Critical patent/BR9907203A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9907203-3A 1998-01-21 1999-01-20 "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " BR9907203A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (1)

Publication Number Publication Date
BR9907203A true BR9907203A (pt) 2000-10-17

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907203-3A BR9907203A (pt) 1998-01-21 1999-01-20 "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. "

Country Status (30)

Country Link
US (2) US6274579B1 (enExample)
EP (2) EP1047428B1 (enExample)
JP (1) JP2002501025A (enExample)
KR (1) KR100568063B1 (enExample)
CN (2) CN1203858C (enExample)
AP (1) AP1229A (enExample)
AT (1) ATE365042T1 (enExample)
AU (1) AU755536B2 (enExample)
BR (1) BR9907203A (enExample)
CA (1) CA2318268A1 (enExample)
CY (1) CY1106828T1 (enExample)
DE (1) DE69936335T2 (enExample)
DK (1) DK1047428T3 (enExample)
EA (1) EA002410B1 (enExample)
EE (1) EE04452B1 (enExample)
ES (1) ES2288012T3 (enExample)
HR (2) HRP20000494B1 (enExample)
HU (1) HUP0100900A3 (enExample)
ID (1) ID26334A (enExample)
IL (2) IL137346A0 (enExample)
IS (1) IS2494B (enExample)
NO (2) NO326878B1 (enExample)
NZ (3) NZ505809A (enExample)
PL (1) PL193622B1 (enExample)
PT (1) PT1047428E (enExample)
SG (1) SG115489A1 (enExample)
SK (1) SK10912000A3 (enExample)
TR (1) TR200002126T2 (enExample)
WO (1) WO1999037305A1 (enExample)
YU (1) YU67102A (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
WO1999038503A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
JP2007509856A (ja) * 2003-10-27 2007-04-19 スミスクライン ビーチャム コーポレーション （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CA2800219C (en) 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
CA2800220C (en) 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines and analogues thereof
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
US6274579B1 (en) 2001-08-14
DE69936335T2 (de) 2008-02-28
KR20010034285A (ko) 2001-04-25
NO20003721D0 (no) 2000-07-20
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
NO326878B1 (no) 2009-03-09
DK1047428T3 (da) 2007-10-08
EP1047428B1 (en) 2007-06-20
AU755536B2 (en) 2002-12-12
NZ529316A (en) 2004-05-28
NZ505809A (en) 2002-09-27
NZ520349A (en) 2004-02-27
HUP0100900A2 (hu) 2002-05-29
HRP20000494A2 (en) 2000-12-31
ATE365042T1 (de) 2007-07-15
JP2002501025A (ja) 2002-01-15
EE04452B1 (et) 2005-04-15
EA002410B1 (ru) 2002-04-25
SK10912000A3 (sk) 2001-04-09
WO1999037305A1 (en) 1999-07-29
EP1047428A1 (en) 2000-11-02
NO20083529L (no) 2000-09-19
PL342012A1 (en) 2001-05-07
EE200000438A (et) 2001-12-17
CN1294513A (zh) 2001-05-09
HRP20000494B1 (en) 2009-02-28
KR100568063B1 (ko) 2006-04-07
US6391875B2 (en) 2002-05-21
HRP20051024A2 (hr) 2006-04-30
PL193622B1 (pl) 2007-02-28
ID26334A (id) 2000-12-14
EA200000691A1 (ru) 2001-04-23
DE69936335D1 (de) 2007-08-02
YU67102A (sh) 2004-12-31
EP1047428A4 (en) 2001-12-19
US20020019396A1 (en) 2002-02-14
IS5568A (is) 2000-07-20
ES2288012T3 (es) 2007-12-16
TR200002126T2 (tr) 2000-12-21
SG115489A1 (en) 2005-10-28
IL161942A0 (en) 2005-11-20
PT1047428E (pt) 2007-09-07
NO20003721L (no) 2000-09-19
HUP0100900A3 (en) 2002-08-28
AP2000001869A0 (en) 2000-09-30
EP1829544A1 (en) 2007-09-05
AP1229A (en) 2003-12-04
AU2328099A (en) 1999-08-09
CY1106828T1 (el) 2012-05-23
CN1255389C (zh) 2006-05-10
CN1203858C (zh) 2005-06-01

Similar Documents

Publication Publication Date Title
TR200002126T2 (tr) Farmasötik olarak aktif morfolinol
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
EP0871488A4 (en) ANAL-SAFE SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANAL-SIDED CANES FROM A MU OPIOID ANAGONIST AND A KAPPA - 2 OPIOID ANAGONIST
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
BR0309345A (pt) Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa
BR0110487A (pt) Composição farmacêutica e método de tratamento de doenças de disfunção cognitiva em um mamìfero
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
JP2002501025A5 (enExample)
ATE371665T1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ATE232384T1 (de) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
IL182908A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
BG105534A (en) 5ht1 means and method for the treatment of migraine
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
HUP0401484A2 (hu) BIBN4096 alkalmazása kombinációban más migrénellenes szerekkel migrén kezelésére és a kombinációt tartalmazó gyógyszerkészítmények
HUT76796A (en) Use of 2,4-diamino pyrimidine 3-oxide or salts thereof for preparing pharmaceutical composition for treating collagen maturation and structruring disorders
ATE301462T1 (de) Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
YU46300A (sh) Farmaceutski aktivni morfolinol

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL 7: C07D265/32; A61K31/5375; A61P25/24

Ipc: C07D 265/32 (2007.10), A61K 31/5375 (2007.10), A61

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS. 8O,11, 13 E 25 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 265/32, A61K 31/5375, A61P 25/34

Ipc: C07D 265/32 (2008.04), A61K 31/5375 (2008.04), A61